FURTRETHONIUM

US Previously Marketed

First approved in 1944

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H14NO
Molecular Weight	140.2029
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+](C)(C)CC1=CC=CO1

InChI

InChIKey=HEDXEAAVEOJUCR-UHFFFAOYSA-N

InChI=1S/C8H14NO/c1-9(2,3)7-8-5-4-6-10-8/h4-6H,7H2,1-3H3/q+1

HIDE SMILES / InChI

Molecular Formula	C8H14NO
Molecular Weight	140.2029
Charge	1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18134262 | https://www.ncbi.nlm.nih.gov/pubmed/21019950 | https://www.ncbi.nlm.nih.gov/pubmed/20256338 | https://www.ncbi.nlm.nih.gov/pubmed/9224827

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/122343 https://www.ncbi.nlm.nih.gov/pubmed/20256338 https://www.ncbi.nlm.nih.gov/pubmed/21019950 https://www.ncbi.nlm.nih.gov/pubmed/18134262	Primary		Approved 8429	Furmethide Approved Use Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma

Doses

Dose	Population	Adverse events
10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	unhealthy n = 21 Health Status: unhealthy Condition: glaucoma Population Size: 21 Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	Disc. AE: Dacryostenosis acquired... AEs leading to discontinuation/dose reduction: Dacryostenosis acquired (71%) Sources: https://pubmed.ncbi.nlm.nih.gov/14829485

AEs

AE	Significance	Dose	Population
Dacryostenosis acquired	71% Disc. AE	10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	unhealthy n = 21 Health Status: unhealthy Condition: glaucoma Population Size: 21 Sources: https://pubmed.ncbi.nlm.nih.gov/14829485

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1W9Q
BOC Sciences	541-64-0
ChemMol	99154117	http://www.chemmol.com/chemmol/99154117.html
Enamine	BBV-82745797
Enamine	EN300-1588178
MolPort	MolPort-006-111-713
NCI Plated 2007	27126
NCI Plated 2007	44407
NovoSeek	10938
ZINC	ZINC000000001500	http://zinc15.docking.org/substances/ZINC000000001500
eMolecules	109817126

PubMed

Title	Date	PubMed
Further studies on the use of furmethide in the treatment of glaucoma.	1946 Apr	21019950
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.	1947 Aug	20256338
Glaucoma treatment by furnethide and diisopropylfluorophosphate.	1949 Jul	18134262
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.	1997 Jul	9224827

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:05 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:05 GMT 2023`
Record UNII	AIQ630U6XO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FURTRETHONIUM

Common Name

English

FURTRIMETHONIUM

Common Name

English

FURTRETHONIUM [MI]

Common Name

English

AMMONIUM, FURFURYLTRIMETHYL-

Systematic Name

English

FURFURYLTRIMETHYLAMMONIUM

Systematic Name

English

2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-

Systematic Name

English

FURTRETONIUM

Common Name

English

FURTRETHONIUM CATION

Common Name

English

FURTRETHONIUM ION

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47792